THE PROSTATE CANCER FOUNDATION (PCF) recently announced the 29 recipients of the 2018 Young Investigator Awards. Sponsored by the PCF, the Young Investigator Awards program provides both financial support and a comprehensive career development program to early career scientists to conduct critical research in prostate cancer.
The 2018 Young Investigator Awards recipients were selected from a pool of 103 applicants from 55 institutions across 11 countries. Recipients of the PCF Young Investigator Award must demonstrate significant promise for having a long-term and impactful career in the prostate cancer research field. Awardees must be within 6 years of completing professional scientific training programs and be under the guidance of at least one mentor. Of the 2018 PCF Young Investigator Awardees, 11 are conducting research to improve prostate cancer outcomes in U.S. veterans. Additional research focus areas include novel precision medicine; new treatments and treatment strategies; immunotherapy; inherited genetic alterations for those at increased risk; and prostate cancer disparities, particularly among African American men.
2018 PCF Young Investigator Awardees
- Saud AlDubayan, MD, Dana-Farber Cancer Institute, Boston
- Mohammad Asim, PhD, University of Surrey, United Kingdom
- Hala Borno, MD, University of California, San Francisco
- Frank Cackowski, MD, PhD, University of Michigan, Ann Arbor, Michigan
- Megan Caram, MD, University of Michigan, Ann Arbor, Michigan
- Kellie Cotter, PhD, University of Bern, Switzerland
- Anis Hamid, MBBS, Dana-Farber Cancer Institute, Boston
- Jennifer Jones, MD, PhD, National Cancer Institute, Rockville, Maryland
- Salma Kaochar, PhD, Baylor College of Medicine, Houston
- Sheng-Yu Ku, PhD, Weill Cornell Medicine, New York
- Hui Li, PhD, University of California, San Francisco
- Brandon Mahal, MD, Dana-Farber Cancer Institute, Boston
- Danil Makarov, MD, New York University, New York
- Megan McNamara, MD, Duke University, Durham, North Carolina
- Kent Mouw, MD, PhD, Dana-Farber Cancer Institute, Boston
- Vivek Narayan, MD, Abramson Cancer Center, University of Pennsylvania, Philadelphia
- David Oh, MD, PhD, University of California, San Francisco
- Eileen Parkes, MD, PhD, Queen’s University Belfast, Belfast, Northern Ireland
- Raquel Perez-Lopez, MD, PhD, Vall d’Hebron Institute of Oncology, Barcelona
- Sethuramasundaram Pitchiaya, PhD, University of Michigan, Ann Arbor, Michigan
- Nicholas Reder, MD, MPH, University of Washington, Seattle
- Zachery Reichert, MD, PhD, University of Michigan, Ann Arbor, Michigan
- Veronica Rodriguez-Bravo, PhD, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia
- Joshua Russo, MD, PhD, Beth Israel Deaconess Medical Center, Boston
- Adam Sharp, MD, PhD, Institute of Cancer Research, London
- Min Yuen Teo, MD, Memorial Sloan Kettering Cancer Center, New York
- Vasanthi Viswanathan, PhD, Broad Institute of MIT & Harvard, Boston
- Scott Wilkinson, PhD, National Cancer Institute, Rockville, Maryland
- David Wise, MD, PhD, New York University, New York. ■
